Bioreduction of 4'-hydroxychalcone

"Bioreduction of 4'-hydroxychalcone" refers to the biochemical conversion of 4'-hydroxychalcone into its saturated dihydrochalcone derivative, 4'-hydroxydihydrochalcone, through the enzymatic reduction of the α,β-unsaturated double bond [6]. This term identifies a biotransformation process or metabolic reaction rather than a discrete therapeutic target protein, receptor, or enzyme [6]. This specific bioreduction is frequently investigated in the field of biocatalysis, where microbial enone reductases from yeast species such as Yarrowia lipolytica and Rhodotorula are utilized to selectively saturate the chalcone's enone moiety [6]. 4'-Hydroxychalcone itself is a bioactive flavonoid derivative with significant anti-inflammatory, antioxidant, and anticancer properties [3, 5]. It exerts its biological effects primarily by acting as a proteasome inhibitor, which prevents the degradation of IκBα and subsequently blocks the nuclear translocation of the NF-κB transcription factor [1, 5]. In animal models, 4'-hydroxychalcone has demonstrated therapeutic potential by attenuating hyperaldosteronism, inflammation, and renal injury [8]. Because the electrophilic α,β-unsaturated carbonyl system is often the pharmacophore responsible for the compound's reactivity with cellular targets, understanding its bioreduction is essential for predicting the metabolic stability, bioavailability, and pharmacological activity of chalcone-based therapeutic leads [6].

Other names

4'-hydroxychalcone biotransformationReduction of 4'-hydroxychalconeSelective reduction of 4'-hydroxychalcone

Inhibition of the 20S proteasome and suppression of the NF-κB signaling pathway (as characterized for the substrate 4'-hydroxychalcone)